# Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

> **NCT05107193** · — · NO_LONGER_AVAILABLE · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** afatinib

## Key facts

- **NCT ID:** NCT05107193
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107193, "Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05107193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*